Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Condition(s):Kidney CancerLast Updated:September 26, 2012Completed
Hide Studies Not Open or Pending
Condition(s):Kidney CancerLast Updated:September 26, 2012Completed
Condition(s):Kidney CancerLast Updated:June 8, 2015Terminated
Condition(s):Carcinoma, Renal Cell; Kidney NeoplasmsLast Updated:March 30, 2023Recruiting
Condition(s):Polymorphism; VEGF; Renal Carcinoma; Renal TransplantationLast Updated:April 14, 2017Unknown status
Condition(s):Kidney Cancer; Renal Cell CarcinomaLast Updated:October 23, 2023Recruiting
Condition(s):Clear Cell Kidney Cancer; Kidney Cancer; Kidney Cancer With PBRM1/BAP1/VHL/SETD2 MutationsLast Updated:July 12, 2023Available
Condition(s):Kidney CancerLast Updated:November 6, 2013Unknown status
Condition(s):Renal Cancer; OncocytomaLast Updated:January 30, 2024Recruiting
Condition(s):Kidney CancerLast Updated:July 26, 2013Completed
Condition(s):Kidney CancerLast Updated:August 12, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.